Safety Profile of Transcranial Near-Infrared Laser Therapy Administered in Combination With Thrombolytic Therapy to Embolized Rabbits
暂无分享,去创建一个
Jackson Streeter | Moon-Ku Han | P. Lapchak | J. Streeter | J. Zivin | Moon‐Ku Han | Paul A Lapchak | Justin A Zivin | Karmen F Salgado | K. F. Salgado
[1] P. Lapchak,et al. Advances in hemorrhagic stroke therapy: conventional and novel approaches , 2007, Expert opinion on emerging drugs.
[2] P. Lyden. Further randomized controlled trials of tPA within 3 hours are required-not! , 2001, Stroke.
[3] P. Lyden,et al. Contraindications of VEGF-based therapeutic angiogenesis: effects on macrophage density and histology of normal and ischemic brains. , 2006, Vascular pharmacology.
[4] Kunio Awazu,et al. Effects of near-infra-red laser irradiation on adenosine triphosphate and adenosine diphosphate contents of rat brain tissue , 2002, Neuroscience Letters.
[5] Rina Das,et al. Clinical and experimental applications of NIR-LED photobiomodulation. , 2006, Photomedicine and laser surgery.
[6] P. Lyden,et al. Comparison of TNK With Wild-Type Tissue Plasminogen Activator in a Rabbit Embolic Stroke Model , 2001, Stroke.
[7] G. Rosenberg. Matrix metalloproteinases in brain injury. , 1995, Journal of neurotrauma.
[8] Jr. MD O. Castro-e-Silva,et al. Spectral response for laser enhancement in hepatic regeneration for hepatectomized rats , 2003, Lasers in surgery and medicine.
[9] William G. Stetler-Stevenson,et al. Tumor necrosis factor-α-induced gelatinase B causes delayed opening of the blood-brain barrier: an expanded therapeutic window , 1995, Brain Research.
[10] P. Lyden,et al. Incidence of cerebral hemorrhage after treatment with tissue plasminogen activator or streptokinase following embolic stroke in rabbits [corrected]. , 1990, Stroke.
[11] Noel T. Whelan,et al. Therapeutic photobiomodulation for methanol-induced retinal toxicity , 2003, Proceedings of the National Academy of Sciences of the United States of America.
[12] P. Lapchak,et al. Reducing Bleeding Complications After Thrombolytic Therapy for Stroke , 2001, CNS drugs.
[13] P. Lyden,et al. Cerebral hemorrhagic risk of aspirin or heparin therapy with thrombolytic treatment in rabbits. , 1991, Stroke.
[14] P. Lapchak,et al. Transcranial Infrared Laser Therapy Improves Clinical Rating Scores After Embolic Strokes in Rabbits , 2004, Stroke.
[15] P. Lapchak,et al. Metalloproteinase Inhibition Reduces Thrombolytic (Tissue Plasminogen Activator)–Induced Hemorrhage After Thromboembolic Stroke , 2000, Stroke.
[16] P. Lapchak. Tumor necrosis factor-α is involved in thrombolytic-induced hemorrhage following embolic strokes in rabbits , 2007, Brain Research.
[17] P. Lapchak,et al. Comparison of Tenecteplase with Alteplase on clinical rating scores following small clot embolic strokes in rabbits , 2004, Experimental Neurology.
[18] P. Lapchak,et al. Transcranial near-infrared light therapy improves motor function following embolic strokes in rabbits: An extended therapeutic window study using continuous and pulse frequency delivery modes , 2007, Neuroscience.
[19] W. P. Van De Merwe,et al. Low power laser irradiation alters the rate of regeneration of the rat facial nerve , 1993, Lasers in surgery and medicine.
[20] Jieli Chen,et al. Low-Level Laser Therapy Applied Transcranially to Rats After Induction of Stroke Significantly Reduces Long-Term Neurological Deficits , 2006, Stroke.
[21] P. Lapchak. 3α-OL-5-β-pregnan-20-one hemisuccinate, a steroidal low-affinity NMDA receptor antagonist improves clinical rating scores in a rabbit multiple infarct ischemia model: Synergism with tissue plasminogen activator , 2006, Experimental Neurology.
[22] Marc Fisher,et al. Infrared Laser Therapy for Ischemic Stroke: A New Treatment Strategy: Results of the NeuroThera Effectiveness and Safety Trial–1 (NEST-1) , 2007, Stroke.
[23] B. Friedman,et al. Stroke-Evoked Angiogenesis Results in a Transient Population of Microvessels , 2007, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.
[24] P. Lyden. Should all stroke patients receive tissue plasminogen activator therapy, despite mild or improving symptoms? , 2006, Nature Clinical Practice Cardiovascular Medicine.
[25] P. Lapchak,et al. Effects of the Spin Trap Agent Disodium- [tert-butylimino)methyl]benzene-1,3-disulfonate N-Oxide (Generic NXY-059) on Intracerebral Hemorrhage in a Rabbit Large Clot Embolic Stroke Model: Combination Studies With Tissue Plasminogen Activator , 2002, Stroke.
[26] Amir Oron,et al. Transcranial application of low‐energy laser irradiation improves neurological deficits in rats following acute stroke , 2006, Lasers in surgery and medicine.
[27] P. Lapchak,et al. The Nonpeptide Glycoprotein IIb/IIIa Platelet Receptor Antagonist SM-20302 Reduces Tissue Plasminogen Activator–Induced Intracerebral Hemorrhage After Thromboembolic Stroke , 2002, Stroke.
[28] J. Zivin. Thrombolytic stroke therapy , 1999, Neurology.
[29] G. Albers,et al. Intravenous tissue-type plasminogen activator for treatment of acute stroke: the Standard Treatment with Alteplase to Reverse Stroke (STARS) study. , 2000, JAMA.
[30] P. Lapchak,et al. Advances in ischemic stroke treatment: neuroprotective and combination therapies , 2007, Expert opinion on emerging drugs.
[31] S. Davis,et al. Alteplase for acute stroke revisited: the first 10 years , 2006, The Lancet Neurology.
[32] P. Lapchak. Hemorrhagic transformation following ischemic stroke: Significance, causes, and relationship to therapy and treatment , 2002, Current neurology and neuroscience reports.
[33] P. Lapchak,et al. Neuroprotective Effects of the Spin Trap Agent Disodium-[(tert-butylimino)methyl]benzene-1,3-disulfonate N-Oxide (Generic NXY-059) in a Rabbit Small Clot Embolic Stroke Model: Combination Studies With the Thrombolytic Tissue Plasminogen Activator , 2002, Stroke.
[34] S Nioka,et al. Study of near infrared technology for intracranial hematoma detection. , 2000, Journal of biomedical optics.
[35] E. Lo,et al. Extracellular proteolysis in brain injury and inflammation: Role for plasminogen activators and matrix metalloproteinases , 2002, Journal of neuroscience research.
[36] U. Oron,et al. Low-energy laser irradiation enhances de novo protein synthesis via its effects on translation-regulatory proteins in skeletal muscle myoblasts. , 2003, Biochimica et biophysica acta.
[37] U. Oron,et al. Promotion of angiogenesis by low energy laser irradiation. , 2002, Antioxidants & redox signaling.
[38] Uri Oron,et al. Modulations of VEGF and iNOS in the rat heart by low level laser therapy are associated with cardioprotection and enhanced angiogenesis , 2006, Lasers in surgery and medicine.
[39] A. Gearing,et al. Immunohistochemistry of matrix metalloproteinases in reperfusion injury to rat brain: activation of MMP-9 linked to stromelysin-1 and microglia in cell cultures , 2001, Brain Research.
[40] G. Press,et al. Tissue plasminogen activator‐mediated thrombolysis of cerebral emboli and its effect on hemorrhagic infarction in rabbits , 1989, Neurology.
[41] U. Oron,et al. Impact of low level laser irradiation on infarct size in the rat following myocardial infarction. , 2001, International journal of cardiology.
[42] J. Rothrock,et al. Intracerebral hemorrhage after experimental embolic infarction. Anticoagulation. , 1987, Archives of neurology.
[43] T. Osborn,et al. Intravenous thrombolytic therapy for stroke: a review of recent studies and controversies. , 1999, Annals of emergency medicine.